Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics

Traditional Chinese Medicine Clinical Trial

— JJGS and POI  

Official title:

Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06102655
• Other study ID #: 2023DZMEC-290
• Secondary ID: 2023DZMEC-290-02
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 24, 2023
• Est. completion date: July 23, 2024

Study information

• Verified date: March 2024
• Source: Dongzhimen Hospital, Beijing
• Contact: Yun Shi, phD
• Phone: 13717926522
• Email: zhyshiyun[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

1. Identify differential metabolites in POI patients.

2. Analysis of differential metabolites and their involved mechanism pathways.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: July 23, 2024
• Est. primary completion date: July 23, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

POI Inclusion Criteria:

1. Patients diagnosed by Western medicine with premature ovarian insufficiency;

2. Patients with Chinese medicine differentiation of kidney deficiency and liver depression;

3. 18 = patients' age = 39 years;

4. Patients who do not use other drugs during treatment;

5. Patients who voluntarily participate in this study, sign an informed consent form, and agree to take the corresponding treatment plan.

The above five items must be met to be included in the POI patient group in this study.

Healthy subjects inclusion criteria:

1. 18 = Age= 39 years old;

2. menstrual regularity;

3. There is no abnormality in sex hormone and AMH examination;

4. Voluntarily participate in this research and sign the informed consent form;

5. Those who match the general information such as age, height, and weight of the patients included in POI.

Exclusion Criteria:

POI exclusion criteria:

1. Patients with congenital gonadal dysplasia or a family history similar to "early menopause";

2. POI patients with acquired organic lesions or ovarian surgery;

3. Patients who have taken Western medicine artificial cycle therapy or other endocrine therapy in the past three months;

4. Patients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system;

5. Patients who are breastfeeding or pregnant;

6. Patients who are allergic to the drugs used in this study or have a history of previous allergy to traditional Chinese medicines.

Those who met any of the above 5 criteria were excluded from this study. Healthy subjects were excluded as (1), (3), (4), (5).

Related Conditions & MeSH terms

• Clinical Syndrome
• Mechanism
• Menopause, Premature
• Metabolomics
• Premature Birth
• Premature Ovarian Insufficiency
• Primary Ovarian Insufficiency
• Traditional Chinese Medicine

Intervention

Drug:
• Jiajian Guishen Formulation
Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.

Locations

Country	Name	City	State
China	Dongzhimen Hospital, Beijing University of Chinese Medicine	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shi Yun

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	follicle stimulating hormone,FSH	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	anti mullerian hormone, AMH	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	Evaluation of the efficacy of Traditional Chinese Medicine symptoms	A sacle score to evalyate the symptoms, results of scores ranges from 0 to 108, higher scores mean more severe condition of POI.The main symptoms include menstrual cycle, menstrual flow reduction. Scoring criteria: ? normal menstrual cycle 0 points, 1-2 weeks ahead or behind the wrong 4 points, 2-3 weeks 8 points, more than 3 weeks 12 points; ? menstrual flow than the previous menstrual flow no change 0 points, menstrual flow reduction = ? 4 points, ? < menstrual flow reduction = ½ 8 points, menstrual flow reduction > ½ 12 points. Secondary symptoms included lumbar and knee pain, dizziness and tinnitus, loss of libido, increased urination, hot flashes and night sweats, and lower back and lower limb pain et. According to the degree of aggravation of symptoms, the total score was assigned as 0,2,4,8.	before and1 month after the treatment
Secondary	Improved Kupperman Scale Scoring	A sacle score to evalyate the symptoms, results of scores ranges from 0 to 39, higher scores mean more severe condition of POI.Referring to the domestic modified Kupperman Symptom Scoring Criteria in Chinese Obstetrics and Gynecology, edited by Cao Zeyi, to observe and rate perimenopausal symptoms before and after treatment and to quantify the degree of decline in ovarian function.Entries include hot flashes and sweating, sensory abnormalities, insomnia, anxiety and depression, dizziness, fatigue, muscle and joint pain, headache, palpitations, ankylosis of the skin, sexual discomfort, and urinary irritation, with different coefficients for each entry, and according to the aggravating degree of the symptom, they are divided into 0, 1, 2, and 3 points, and the coefficients corresponding to the scoring of the degree of each item are multiplied by a fixed score of the symptom to add up to the total score.	before and 1 month after the treatment
Secondary	estradiol, E2	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	luteinizing hormone, LH	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	testosterone, T	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	malondialdehyde	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	superoxide dismutase	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	reduced glutathione, GSH	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	ceruloplasmin	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	copper	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	metabolite level	Blood samples are collected before and after treatment.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	Differential metabolites and their related indexes of mechanism pathways	The results of differential metabolites and their related indexes of mechanism pathways cann't be predicted until the metabolomics test finish, because the test include hundreds of metabolites. Metabolomics results will be tested by using liquid chromatography coupled with mass spectrometry (LC-MS) to identify potential markers.All multivariate analyses and modeling on the normalized data were carried out using software SIMCA-P. Supervised analysis (orthogonal partial least squares discriminate analysis, OPLS-DA) was applied to distinguish metabolic difference between normal group and POI group. SPSS 22.0 (SPSS Inc) software was used for receiver operating characteristic (ROC) curve analyses and binary logistic regression analyses. Then their related indexes of mechanism pathways will be tested in blood samples.	Differential metabolites will be tested on the 2~4th day of menstruation (amenorrhea patients before and after taking medication), related indexes of mechanism pathways will be tested after the analyses of differential metabolities
Secondary	Number of participants with abnormal laboratory test of blood routine examination results	Blood samples are collected before and after treatment. white blood cell count (WBC), red blood cell (RBC) and platelet count/blood platelet count (PLT) are included.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)
Secondary	Number of participants with abnormal Liver and kidney function (by laboratory test results)	Blood samples are collected before and after treatment. creatinine(CREA), uric acid (UA), alanine amiotransferase(AST), aspartate aminotransferase (AST) and ?-glutamyl transpeptadase (GGT) are included.	On the 2~4th day of menstruation (amenorrhea patients before and after taking medication)